*Dosimetry*

process. Thus we considered type B uncertainty negligible, and we reduced the uncertainty to statistical uncertainty. A description of the methodology used to estimate the type B uncertainties is mentioned in the updated report of the TG-43 [21] and the HEBD working group report [1].
